Rabbit monoclonal antibodies, available from Abcam following acquisition of Epitomics

September 4, 2012: Abcam is pleased to announce that following the completion of the acquisition of Epitomics, customers in Europe are now able to purchase Epitomics’ line of high quality RabMAbs® (Rabbit Monoclonal Antibodies) directly from our website.

RabMAbs® provide the combined benefits of superior antigen recognition of the rabbit immune system with the specificity and consistency of a monoclonal antibody, bringing you the highest quality antibody possible.

This move will enhance the service and support for our European customers who will now be able to receive Epitomics research products in a much shorter time frame than previously possible. Most European countries will now receive Epitomics research products via Abcam’s next day delivery service. Abcam’s multi-lingual technical support teams will also be available to answer questions regarding Epitomics products.

Epitomics products can be found directly on Abcam’s website or on Epitomics’ website. Customers in Europe wishing to place orders for Epitomics research products will be able to purchase directly with Abcam.

For a complete list of countries where Epitomics research products can be ordered from and for further details, please visit Epitomics or Abcam. Please note that Epitomics IVD products will continue to be sold through Epitomics existing distribution network.

The acquisition of Epitomics, Inc. now known as Epitomics – an Abcam Company, extends Abcam’s product portfolio, including RabMAbs® research antibodies, EP Clone antibodies for Immunohistochemistry (In Vitro Diagnostics Range) and Custom Antibody Development Services, in line with Abcam’s vision of becoming the world’s leading supplier of life science research tools.

About Epitomics

Epitomics, Inc. is a biotechnology company dedicated to developing breakthrough rabbit monoclonal antibody technology for research and diagnostic applications. The Company’s core technology is its unique and proprietary RabMAbs® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays.

Epitomics, Inc. was founded in 2001, headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People’s Republic of China.

Epitomics, Inc. is now known as Epitomics – an Abcam Company.

New range of Biochemicals now available from Abcam

Abcam Biochemcials

January 9, 2012: Abcam has today launched a new range of exceptional quality and high performance biochemicals.  The products include high purity agonists, antagonists, channel blockers, enzyme inhibitors and signaling tools for life science researchers.

The acquisition extends Abcam’s product portfolio into bioactive small molecules and is in line with the Company’s vision of becoming the world’s leading supplier of protein research tools.

Commenting on the launch, Steve Roome (Abcam Biochemicals General Manager) said:

“The launch extends Abcam’s product portfolio into small molecules and offers customers a great choice of high purity pharmacological and signaling life science reagents.  Customers will benefit from the same fast delivery, product guarantee and multilingual scientific support as they do for all Abcam products.

We intend to rapidly expand the range and are confident Abcam Biochemicals will fast become the researchers choice for high quality and high performance biochemical tools.”

Ordering
Researchers who previously ordered Ascent Scientific products can now order Abcam Biochemicals via the Abcam website and through authorized distributors.  Products carry the same ASC product code as before for ease of search.

For further information contact:

Abcam: +44 01223 696000

Abcam acquires Ascent Scientific, a specialist provider of biochemicals

September 13, 2011: Abcam plc, is pleased to announce it has entered into an agreement to acquire Ascent Scientific Ltd, a specialist provider of biochemical reagents. The acquisition extends Abcam’s product portfolio into small molecules and is in line with the Company’s vision of becoming the world’s leading supplier of protein research tools.

Ascent Scientific has a diverse and rapidly growing range of over 400 bioactive small molecules, manufactured both in-house and through outsourcing. A specialist production and analytical facility is based in Bristol, UK, which also serves as the primary distribution outlet and customer support base. Their products are used by life science researchers for modulating the function of proteins.

The product range will be integrated into Abcam’s website and available through authorized distributors by early 2012.

Commenting on the announcement Jonathan Milner, Chief Executive Officer, said:

“Ascent Scientific has built an excellent reputation as a provider of high quality biochemical products and has been quick to bring new, best-in-class reagents to market backed by specialist technical support, which is very much in line with Abcam’s ethos. Many Abcam customers are already using bioactive small molecules in their research so Ascent Scientific’s range of reagents is a great complement to our existing catalogue of protein research tools.“

“By becoming part of Abcam, Ascent Scientific will benefit from our proven eCommerce model and global market reach. I look forward to welcoming its talented employees into the Abcam team and making its existing and pipeline products available to our customers.”

About Ascent Scientific

Ascent Scientific was a privately held biochemical company headquartered in Bristol (UK) who produced and distributed receptor ligands for use by academic researchers. Ligands are substances which bind to proteins, often regulating their function or activity. Ascent Scientific products are used by life science researchers working in academia, pharmaceutical and chemical related industries.

Ascent Scientific was founded in 2005 with the mission of progressing scientific research by providing high quality products supported by expert customer support. Their UK office houses production and analytical facilities, as well as Marketing, Business Development and administrative functions. Their management team has extensive experience in the pharmaceutical, agrochemical and chemistry related industries.

For further information contact:

Abcam: +44 (0) 1223 696000

Ascent Scientific

Abcam acquires MitoSciences in deal which enhances immunoassay portfolio

24 May 2011: Abcam is pleased to announce it has entered into an agreement to acquire MitoSciences Inc. a leading provider of cutting edge mitochondrial research tools.  This represents a further step towards Abcam’s mission of becoming the leading supplier of protein research and detection tools.

MitoSciences has over 200 products in the areas of metabolism and apoptosis, including antibody cocktails, sandwich ELISA kits, in-cell ELISA, flow cytometry antibodies and enzyme activity assays.  The acquisition enhances Abcam’s existing portfolio in these areas and complements an increasing range of non-antibody products.  The MitoSciences product range will be available via Abcam’s website and authorized distributors within six weeks.  Products will carry the MitoSciences logo.

Jonathan Milner, Chief Executive of Abcam said:

“The combined companies will be the market leader in mitochondrial research and will extend our in-house manufacturing and product development capabilities in the exciting area of immunoassay platforms.

“We remain committed to providing customers with the highest quality products available and will continue to deliver MitoSciences’ excellence in product performance and customer support. 

“We are delighted to have this opportunity to extend our product offering to customers and strengthen our business in this research area.  We look forward to welcoming the employees of MitoSciences into the Abcam team and aim for a smooth transition for existing customers.”

About MitoSciences

MitoSciences was a privately held biotech company based in Eugene, Oregon (US).  The Company produce and distribute immunoassay platforms and high performance monoclonal antibodies.  It was founded in 2004 with the mission of advancing mitochondrial research and developing products that support critical research in cancer, neurodegeneration and metabolic disorders.

For further information contact:

Abcam +44 (0) 1223 696000

MitoSciences + 1 541 284 1800

Jonathan Milner wins Entrepreneur of the Year award

  • Abcam’s CEO wins the prestigious AIM award for Entrepreneur of the Year, 2010

Jonathan says; “It’s an honour to be voted Entrepreneur of the Year and I accept the award on behalf of everyone at Abcam. The success of Abcam is a result of all employees striving for excellence in every aspect of our business, which I am pleased to acknowledge in receiving this award”.

AIM awards

Sponsored by PwC, the AIM awards dinner is now in its 15th year attracting 1,300 guests. The AIM club gathers to celebrate outstanding achievement on the world’s most successful growth market.

View the rest of the AIM winners.

300th employee hired

Abcam’s Jonathan Milner wins CEO of the Year

  • European Mediscience Awards congratulate Jonathan Milner in winning the Chief Executive Officer of the year award at the Mediscience Awards 2010

Left to right; David Wilson, Chief Executive, Piper Jaffray Ltd; Kate Silverton (presenter); Jonathan Milner, Abcam plc; and Lisa Baderoon, Buchanan Communications.

Jonathan Milner said “It’s a great privilege to win this award. It reflects the hard work and commitment of everyone at the company, all of whom I would like to thank.”

On behalf of the voting panel Kate Silverton, BBC personality and Awards presenter, said: “Jonathan is a highly experienced entrepreneur, business leader and co-founder of Cambridge-based Abcam. This was a very competitive shortlist all of whom would have been deserved winners of this award. However Jonathan has demonstrated outstanding leadership in the last 12 months and this has been reflected in the performance of the company”.

The European Mediscience Awards is the largest gathering of publicly quoted healthcare, biotech and life science companies in Europe. Now in its 9th year, the dinner was held at the Hotel Intercontinental, London on Thursday June 24th . It celebrates the best in the sector and highlights the achievements of individuals and companies.

Abcam founder wins ‘CEO of the Year’ at Quoted Company Awards 2010

  • Award celebrates success within the quoted smaller companies arena

Jonathan Milner, the CEO and principal founder of Abcam, was awarded ‘CEO of the Year’ at the Grant Thornton Quoted Company Awards.

The awards recognize the achievements of smaller quoted companies below the FTSE 350 through to AIM and PLUS, and the ceremony was held at the grand location of the Royal Courts of Justice in London on January 28.

The judges were impressed by his long-term strategic decisions, Abcam’s overseas development and the achievement of building a world-class company. They also highlighted that as well as rapid growth, Abcam delivers a yield to its investors.

Jonathan Milner commented: ‘I am absolutely delighted and honored to receive this award and thank everybody in Abcam for their dedication and support, without which this would not have been possible’.

CEO of the Year award 2010Jonathan Milner, Abcam CEO, collects the award from Karen Brady, Vice-chairman, West Ham United and Ian Throssell, Director of Market-Making, Winterflood.

Image courtesy of Quoted Company Awards

Abcam investor relations

Abcam named ‘Company of the Year’ at 2009 AIM Awards

  • AIM stock exchange celebrates Abcam’s strength of business and potential for growth

Abcam picked up the top prize at the 2009 AIM Awards, winning ‘Company of the Year’. The award, described as the ‘ultimate accolade’ for any company on the AIM market, was announced at the AIM Awards Dinner in London in October 15. It is presented to a company that has demonstrated they are a responsible, fully accountable, dynamic business with excellent potential for growth.

Jonathan Milner, Abcam’s CEO commented: ‘The transformation of Abcam over the past 10 years from a fledgling company selling antibodies out of an ice bucket to being voted AIM company of the year is truly amazing and is in no small part due to the passion and dedication of the staff that have been part of the company over the decade’.

Abcam’s continued growth reflects on our high-quality products and excellent customer service and technical support. Read more about the Abcam story.

AIM company of the year

Jonathan Milner, CEO, collects the award from Emily Maitlis, presenter, Neil Sutton, PricewaterhouseCoopers and Deryck Noble-Nesbitt, Close Asset Management Ltd.

AIM is the London Stock Exchange’s international market for smaller growing companies, and combines access to one of the deepest pools of capital in the world with a regulatory framework and approach uniquely suited to smaller companies.

Abcam investor relations